Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jan 25;10:448. doi: 10.1038/s41467-018-08271-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — FGL2 is expressed by glioma cells. a FGL2 protein levels were detected by western blot in human peripheral blood monocytes (PBMCs) from healthy donors, normal endothelial cells (HMVECs), normal neurons (HCN-1A), and four glioma stem cell lines (GSC7-2, GSC11, GSC20, and GSC28). Western blots shown are representative, and quantities are summarized as ratio changes from three independent experiments. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a protein-loading control. b Percentage of FGL2⁺ cells in cultured human GSCs. c Representative flow cytometry plots of FGL2 expression on CD45⁺, CD31⁺, or GFAP⁺ cells from tumors of patients with newly diagnosed GBM. Data (n = 5) are presented as the mean ± S.D. and analyzed by one-way ANOVA. d Sections of clinical GBM samples were double stained for co-expression of FGL2 (red) and GFAP (green), or of FGL2 (red) and CD45 (green), or of FGL2 (red) and CD31 (green). Nuclei were counterstained with DAPI (blue). White arrows point to co-localization. Scale bars, 50 μm. Data are presented as the mean ± S.D., and representative images are shown (n = 5). A one-way ANOVA was used to calculate the two-sided P values. Significant results were presented as **P < 0.01, ***P < 0.001